An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) will have its Chairman and CEO, Dr. Scott Braunstein, participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference on May 15 at 1:35 p.m. Eastern Time. The event will be accessible through Marinus' website, with a replay available for 90 days.
Positive
None.
Negative
None.
RADNOR, Pa.--(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference.
The fireside chat will take place on Wednesday, May 15 beginning at 1:35 p.m. Eastern Time.
A link to the event can be accessed on the Investors and Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com.
Company
Investors and Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
FAQ
When is Marinus Pharmaceuticals participating in the RBC Capital Markets 2024 Global Healthcare Conference?
Marinus Pharmaceuticals will be participating on May 15 at 1:35 p.m. Eastern Time.
Who will be representing Marinus Pharmaceuticals at the conference?
Dr. Scott Braunstein, Chairman and CEO, will be representing Marinus Pharmaceuticals.
Where can I access the event?
The event can be accessed on the Investors and Media page of Marinus' website at ir.marinuspharma.com/events-and-presentations.
Will the webcast be available for replay?
Yes, a replay of the webcast will be available approximately two hours after the event and will be archived for up to 90 days.
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
